华海药业(600521.SH)：第三季度净亏损2913.13万元

Core Viewpoint - Huahai Pharmaceutical (600521.SH) reported a decline in revenue and net profit for Q3 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for Q3 2025 was 1.893 billion yuan, representing a year-on-year decrease of 10.70% [1] - The net profit attributable to shareholders of the listed company was -29.1313 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -93.3738 million yuan [1]